Dachaigh › Galar Ae Steatotic › North Carolina
Sgrùdaidhean clionaigeach Galar Ae Steatotic ann an North Carolina
Tha 13 sgrùdaidhean airson Galar Ae Steatotic a’ lorg phàirtichean aig làraichean ann an North Carolina.
Bailtean ann an North Carolina
Teacsa sgrùdaidh oifigeil (Beurla)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Asheville
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- agus 2 a bharrachd
A’ fastadhÌre 3
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- 89bio Clinical Study Site, Fayetteville
- agus 3 a bharrachd
A’ fastadhÌre 3
Aoisean 18 gu 80 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06318169A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Morehead City
A’ fastadhÌre 3
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT07704892Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Duke Liver Center, Durham
A’ fastadhÌre 2
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT05832229A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Duke University - Main Hospital and Clinics, Durham
- Monroe Biomedical Research, Monroe
- Carteret Medical Group, Morehead City
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Chapel Hill
- Akero Clinical Study Site, Charlotte
- Akero Clinical Study Site, Charlotte
- agus 5 a bharrachd
A’ fastadhÌre 3
Aoisean 18 gu 80 · Gach gnè · Air ùrachadh 21 Sult 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Morehead City
A’ fastadhÌre 3
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Coastal Research Institute, Fayetteville
A’ fastadhÌre 2
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT07288138A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Chapel Hill
A’ fastadhÌre 2
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 3 Lùna 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Morehead City
A’ fastadhÌre 3
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 27 Iuch 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Wilson
A’ fastadhÌre 2
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 8 Iuch 2026 · NCT06920043Androgens and NAFLD Longitudinal Cohort Study
- Duke University, Durham
A’ fastadhSgrùdadh amharc
Aoisean 18 gu 42 · Banairean · Air ùrachadh 13 Gibl 2026 · NCT06124261Siemens Biomarker Multi-modality
- Duke University Medical Center, Durham
A’ fastadh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 3 Gibl 2026 · NCT07495332Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.